Gilead Sciences: Strategic Gains From Lenacapavir And Trodelvy Justify A Buy RatingSeeking Alpha • 06/24/24
GILD Stock Today: Why A Broken Wing Butterfly Might Make Money In Gilead Sciences StockInvestors Business Daily • 06/21/24
Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?Zacks Investment Research • 06/21/24
Gilead surges as HIV prevention therapy shows 100% efficacy in late-stage trialProactive Investors • 06/20/24
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% EffectiveInvestors Business Daily • 06/20/24
Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV PreventionBusiness Wire • 06/20/24
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss ContenderInvestors Business Daily • 06/17/24